We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+49.01%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.43B
AUM Growth
-$263M
Cap. Flow
-$141M
Cap. Flow %
-9.8%
Top 10 Hldgs %
54.7%
Holding
66
New
3
Increased
9
Reduced
40
Closed
4

Top Buys

Rank Stock Value
1
NGNE icon
Neurogene
NGNE
+$13.2M
2
CBLL
CeriBell Inc
CBLL
+$11.9M
3
RAPT
RAPT Therapeutics
RAPT
+$9.48M
4
LIVN icon
LivaNova
LIVN
+$8.64M
5
SLN
Silence Therapeutics
SLN
+$6.45M

Top Sells

Rank Stock Value
1
AUGX
Augmedix, Inc. Common Stock
AUGX
+$38.5M
2
CTLT
CATALENT, INC.
CTLT
+$36.1M
3
SRRK icon
Scholar Rock
SRRK
+$22.4M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.2M
5
FOLD
Amicus Therapeutics
FOLD
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$7.04B
$197M 13.7%
4,549,881
-688,956
-13% -$22.4M
KRYS icon
2
Krystal Biotech
KRYS
$10.4B
$118M 8.22%
753,175
-57,070
-7% -$10.1M
NRIX icon
3
Nurix Therapeutics
NRIX
$2.72B
$79M 5.51%
4,192,627
-88,354
-2% -$2.03M
ZYME icon
4
Zymeworks
ZYME
$2.02B
$70.9M 4.94%
4,840,463
-261,448
-5% -$3.66M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$66.5M 4.63%
7,054,890
-1,191,702
-14% -$12.4M
REPL icon
6
Replimune Group
REPL
$1.46B
$59.4M 4.14%
4,905,527
+124,344
+3% +$1.51M
IMNM icon
7
Immunome
IMNM
$3.13B
$51.3M 3.57%
4,828,026
-61,528
-1% -$744K
STOK icon
8
Stoke Therapeutics
STOK
$2.04B
$50.7M 3.53%
4,593,629
-119,880
-3% -$1.47M
LIVN icon
9
LivaNova
LIVN
$4.43B
$48.3M 3.37%
1,043,539
+168,500
+19% +$8.64M
KYMR icon
10
Kymera Therapeutics
KYMR
$9.82B
$44.3M 3.09%
1,100,432
-292,824
-21% -$13.2M
PLRX icon
11
Pliant Therapeutics
PLRX
$68.7M
$38.1M 2.66%
2,895,478
-302,013
-9% -$4.12M
BEAM icon
12
Beam Therapeutics
BEAM
$3.03B
$37.9M 2.64%
1,528,567
-82,446
-5% -$2.1M
RGNX icon
13
Regenxbio
RGNX
$638M
$37.1M 2.58%
4,794,780
-98,122
-2% -$921K
AKRO
14
DELISTED
Akero Therapeutics
AKRO
$34.4M 2.39%
1,235,209
-152,270
-11% -$4.61M
BHVN icon
15
Biohaven
BHVN
$2.33B
$33.8M 2.35%
904,496
-129,723
-13% -$6.05M
ANNX icon
16
Annexon
ANNX
$942M
$32.3M 2.25%
6,300,644
-126,818
-2% -$780K
ADCT icon
17
ADC Therapeutics
ADCT
$146M
$31.2M 2.17%
15,666,731
-2,486
-0% -$6.5K
NGNE icon
18
Neurogene
NGNE
$732M
$30.2M 2.1%
1,319,763
+355,416
+37% +$13.2M
BSX icon
19
Boston Scientific
BSX
$67.9B
$27.9M 1.95%
312,683
-18,190
-5% -$1.6M
COGT icon
20
Cogent Biosciences
COGT
$6.02B
$27.7M 1.93%
3,554,836
-929,544
-21% -$9.26M
ABSI icon
21
Absci
ABSI
$1.49B
$21.6M 1.51%
8,253,316
– –
FATE icon
22
Fate Therapeutics
FATE
$291M
$21.2M 1.48%
12,872,946
-296,111
-2% -$746K
IGMS
23
DELISTED
IGM Biosciences
IGMS
$18M 1.26%
2,952,131
-120,347
-4% -$1.43M
ETNB
24
DELISTED
89bio
ETNB
$16.9M 1.18%
2,167,176
+597,326
+38% +$4.92M
SLN
25
Silence Therapeutics
SLN
$834M
$16.5M 1.15%
2,399,317
+500,000
+26% +$6.45M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2024 Portfolio in Review

As of Q4 2024, Redmile Group held 66 positions worth $1.43B, down 15% from $1.7B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group withdrew a net $141M in Q4 2024, closing 4 positions and reducing 40 holdings. Its most notable exit was Augmedix, Inc. Common Stock, an estimated $38.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in CeriBell Inc worth $11.3M.

  • Redmile Group's largest Q4 2024 buy was CeriBell Inc: 435,239 shares worth $11.3M.
  • Redmile Group added most to Neurogene in Q4 2024, an estimated $13.2M increase.
  • Redmile Group's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $22.4M.
  • Redmile Group fully exited Augmedix, Inc. Common Stock in Q4 2024, selling an estimated $38.5M.
  • Redmile Group's ten largest holdings make up 55% of its $1.43B portfolio in Q4 2024.
  • Redmile Group opened 3 new positions and closed 4 in Q4 2024.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $1.43B.

Based on Redmile Group's 13F filing for Q4 2024, filed 14 Feb 2025.